[Asia Economy Reporter Minji Lee] Naturecell is experiencing a decline following news that its domestic COVID-19 treatment clinical trial plan has been rejected.
At 9:11 AM on the 3rd, Naturecell was trading at 8,730 KRW, down 3.22% from the previous trading day.
On this day, Naturecell announced that it decided to reject the Phase 1/2a clinical trial plan aimed at exploring the safety and efficacy of allogeneic adipose-derived mesenchymal stem cell (Astrostem-V) treatment in pneumonia patients caused by COVID-19 infection. The company stated, "The clinical trial plan was rejected due to insufficient data on some items."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
